stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) Revenue
Elanco Animal Health Incorporated's revenue for fiscal 2025 was $4.7B, up 6.22% from $4.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $5.0B. Over the past ten years it has ranged from $2.9B (fiscal 2017) to $4.8B (fiscal 2021); the current reading is higher than 91% of that period. Revenue has risen for 3 consecutive fiscal years. Elanco Animal Health Incorporated ranks 7th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $4.7B | 6.22% |
| FY2024 | $4.4B | 0.50% |
| FY2023 | $4.4B | 0.14% |
| FY2022 | $4.4B | (7.41%) |
| FY2021 | $4.8B | 45.64% |
| FY2020 | $3.3B | 6.51% |
| FY2019 | $3.1B | 0.14% |
| FY2018 | $3.1B | 6.15% |
| FY2017 | $2.9B | (0.84%) |
| FY2016 | $2.9B | 0.15% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.4B | (0.22%) |
| Mar 2026 | $1.4B | 19.84% |
| Dec 2025 | $1.1B | 0.62% |
| Sep 2025 | $1.1B | (8.38%) |
| 31 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| VTRS Viatris Inc. compare | $14.7B |
| ELAN Elanco Animal Health Incorporated | $5.0B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| ALKS Alkermes plc compare | $1.8B |
| LNTH Lantheus Holdings, Inc. compare | $1.6B |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $946.0M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ELAN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement